- Home
- INCY vs FDS Comparison
INCY vs FDS Comparison
Compare INCY & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- FDS
- Stock Information
- Founded
- INCY 1991
- FDS 1978
- Country
- INCY United States
- FDS United States
- Employees
- INCY N/A
- FDS N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- FDS Computer Software: Programming Data Processing
- Sector
- INCY Health Care
- FDS Technology
- Exchange
- INCY Nasdaq
- FDS Nasdaq
- Market Cap
- INCY 16.1B
- FDS 17.6B
- IPO Year
- INCY 1993
- FDS 1996
- Fundamental
- Price
- INCY $86.85
- FDS $282.36
- Analyst Decision
- INCY Buy
- FDS Hold
- Analyst Count
- INCY 20
- FDS 10
- Target Price
- INCY $80.67
- FDS $356.78
- AVG Volume (30 Days)
- INCY 1.7M
- FDS 839.4K
- Earning Date
- INCY 10-28-2025
- FDS 09-18-2025
- Dividend Yield
- INCY N/A
- FDS 1.55%
- EPS Growth
- INCY 900.04
- FDS 11.79
- EPS
- INCY 4.37
- FDS 15.55
- Revenue
- INCY $4,584,996,000.00
- FDS $2,321,748,000.00
- Revenue This Year
- INCY $16.36
- FDS $6.60
- Revenue Next Year
- INCY $10.82
- FDS $5.37
- P/E Ratio
- INCY $19.80
- FDS $18.20
- Revenue Growth
- INCY 18.87
- FDS 5.39
- 52 Week Low
- INCY $53.56
- FDS $280.03
- 52 Week High
- INCY $88.66
- FDS $499.87
- Technical
- Relative Strength Index (RSI)
- INCY 59.41
- FDS 22.33
- Support Level
- INCY $81.09
- FDS $282.01
- Resistance Level
- INCY $88.66
- FDS $289.54
- Average True Range (ATR)
- INCY 1.90
- FDS 10.42
- MACD
- INCY 0.02
- FDS -0.70
- Stochastic Oscillator
- INCY 76.09
- FDS 3.40
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for roughly 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.